secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001682852-22-000055
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna and Merck report Phase 2b mRNA cancer vaccine met primary endpoint in melanoma, reducing recurrence risk by 44%
--------------------------------------------------------------------------------

- mRNA-4157/V940 + KEYTRUDA reduced risk of recurrence or death by 44% vs KEYTRUDA alone (HR=0.56, p=0.0266) in stage III/IV melanoma.
- First randomized trial evidence for an mRNA cancer treatment; companies plan Phase 3 in melanoma in 2023 and expansion to other tumor types.
- Serious treatment-related AEs: 14.4% in combination arm vs 10% with KEYTRUDA alone.
- Merck and Moderna share costs and profits equally under worldwide collaboration announced in October.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285222000055/0001682852-22-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285222000055/mrna-20221213.htm
  HTML page:      https://secwatch.observer/filing/0001682852-22-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer